Related Experiment Video
Updated: Jun 17, 2026

Semi-automated Optical Heartbeat Analysis of Small Hearts
Published on: September 16, 2009
Vision and creation of the American Heart Association pharmaceutical roundtable outcomes research centers
Eric D Peterson1, John A Spertus, David J Cohen
1Duke Outcomes Research Center, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27705, USA. peter016@mc.duke.edu
Background:
The field of outcomes research seeks to define optimal treatment in practice and to promote the rapid full adoption of efficacious therapies into routine clinical care. The American Heart Association (AHA) formed the AHA Pharmaceutical Roundtable (PRT) Outcomes Research Centers Network to accelerate attainment of these goals. Participating centers were intended to carry out state-of-the-art outcomes research in cardiovascular disease and stroke, to train the next generation of investigators, and to support the formation of a collaborative research network.
Program:
After a competitive application process, 4 AHA PRT Outcomes Research Centers were selected: Duke Clinical Research Institute; Saint Luke's Mid America Heart Institute; Stanford University-Kaiser Permanente of Northern California; and University of California, Los Angeles. Each center proposed between 1 and 3 projects organized around a single theme in cardiovascular disease or stroke. Additionally, each center will select and train up to 6 postdoctoral fellows over the next 4 years, and will participate in cross-collaborative activities among the centers.
Conclusions:
The AHA PRT Outcomes Research Centers Network is designed to further strengthen the field of cardiovascular disease and stroke outcomes research by fostering innovative research, supporting high quality training, and encouraging center-to-center collaborations.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiovascular Drugs: Classification based on Therapeutic Indications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease IV: Preventive Measures

